Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Trial Profile

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Entinostat (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 05 Oct 2017 According to a Syndax Pharmaceuticals media release, first patient has been dosed.
    • 28 Sep 2017 New source identified and integrated(ClinicalTrials.gov NCT03291886)
    • 25 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top